soul trial oral semaglutide cardiovascular outcomes 2024 nejm results Reduces CV Events in T2DM – (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine 🧪 T2DM + ASCVD/CKD 💊 Oral semaglutide 14 mg vs placebo 📉 Optimal Medical Therapy Targeting Metabolic

Being aware of how each med is administered, what the dosage is, and what advantages and side effects to expect, will ensure you have the information you need for a discussion with your healthcare provider about which GLP-1 medication might be the best choice for your medical profile and personal health goals

The reminder banners that nudge you to update personal details or review responsible tools appear at just the right cadence, never intrusive

in fact, it's impossible to isolate these chemicals and tie their effects together

Many patients who do not need dramatic weight reduction may still achieve modest yet meaningful progress